Evaluation of tulathromycin for the treatment of pneumonia following experimental infection of swine with Mycoplasma hyopneumoniae.
Tulathromycin was evaluated in the treatment of pneumonia in weaned pigs inoculated intranasally with Mycoplasma hyopneumoniae. Five days postchallenge, the pigs were randomized to treatment with a single IM administration of saline, a single IM administration of tulathromycin (2.5 mg/kg; day 0), or three IM administrations of enrofloxacin (5.0 mg/kg; days 0, 1, 2). Pigs were necropsied on day 12 or 13. Unchallenged controls remained healthy with no lung pathology. Compared with saline, coughing, mean lung lesion score, and proportional lung weight were significantly reduced and weight gain was significantly greater for tulathromycin-treated pigs (P < .05). Compared with enrofloxacin, there were no significant differences in proportional lung weight or weight gains, but coughing and lung lesion scores were greater for tulathromycin-treated pigs (P < .05). Tulathromycin was effective in the treatment of pneumonia following experimental infection with M. hyopneumoniae.
McKelvie
Jo
J
Veterinary Medicine Research and Development, Pfizer Ltd, Sandwich, Kent, UK.
Morgan
Jeremy H
JH
Nanjiani
Ian A
IA
Sherington
John
J
Rowan
Tim G
TG
Sunderland
Simon J
SJ
D000818:Animals; D000831:Animals, Newborn; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004187:Disaccharides / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D007273:Injections, Intramuscular / Q000662:veterinary; D045705:Mycoplasma hyopneumoniae; D045729:Pneumonia of Swine, Mycoplasmal / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index; D013552:Swine; D016896:Treatment Outcome; D018942:Macrolides
D000900:Anti-Bacterial Agents; D004187:Disaccharides; D006571:Heterocyclic Compounds; C485204:tulathromycin; D018942:Macrolides